Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (441-450 of 632) with videos related to

Pageof 64
Sort By:
Alimentary Pharmacology & Therapeutics|November 13, 2018
Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and deathCornelius Engelmann, Stefan Schob, Ines Nonnenmacher, et al.
Hepatology (Baltimore, Md.)|January 22, 2017
The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis BKhaled Thabet, Henry Lik Yuen Chan, Salvatore Petta, et al.
Journal of Cancer Research and Clinical Oncology|September 20, 2021
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trialOsman Öcal, Daniel Rössler, Antonio Gasbarrini, et al.
Zeitschrift Fur Gastroenterologie|May 15, 2025
Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-RegistryEva Katharina Messer, David Petroff, Jörn Schattenberg, et al.
Gut|February 23, 2011
Pregnancy in primary sclerosing cholangitisBjörn E Wellge, Martina Sterneck, Andreas Teufel, et al.
Gastroenterology|July 26, 2011
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeksChristoph Sarrazin, Susanne Schwendy, Bernd Möller, et al.
The Journal of Clinical Investigation|October 28, 2010
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in miceMarie-Luise Berres, Rory R Koenen, Anna Rueland, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|May 23, 2022
Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosisHenry L Y Chan, Arndt Vogel, Thomas Berg, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|May 8, 2012
[Mutation testing for non-small-cell lung cancer]Odd Terje Brustugun, Åslaug Helland, Lars Fjellbirkeland, et al.
Alcoholism, Clinical and Experimental Research|May 1, 2008
No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver diseaseFelix Stickel, Christoph H Osterreicher, Juliane Halangk, et al.
Pageof 64

Showing results (441-450 of 632) with videos related to

Sort By:
Pageof 64
Alimentary Pharmacology & Therapeutics|November 13, 2018
Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and deathCornelius Engelmann, Stefan Schob, Ines Nonnenmacher, et al.
Hepatology (Baltimore, Md.)|January 22, 2017
The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis BKhaled Thabet, Henry Lik Yuen Chan, Salvatore Petta, et al.
Journal of Cancer Research and Clinical Oncology|September 20, 2021
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trialOsman Öcal, Daniel Rössler, Antonio Gasbarrini, et al.
Zeitschrift Fur Gastroenterologie|May 15, 2025
Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-RegistryEva Katharina Messer, David Petroff, Jörn Schattenberg, et al.
Gut|February 23, 2011
Pregnancy in primary sclerosing cholangitisBjörn E Wellge, Martina Sterneck, Andreas Teufel, et al.
Gastroenterology|July 26, 2011
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeksChristoph Sarrazin, Susanne Schwendy, Bernd Möller, et al.
The Journal of Clinical Investigation|October 28, 2010
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in miceMarie-Luise Berres, Rory R Koenen, Anna Rueland, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|May 23, 2022
Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosisHenry L Y Chan, Arndt Vogel, Thomas Berg, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|May 8, 2012
[Mutation testing for non-small-cell lung cancer]Odd Terje Brustugun, Åslaug Helland, Lars Fjellbirkeland, et al.
Alcoholism, Clinical and Experimental Research|May 1, 2008
No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver diseaseFelix Stickel, Christoph H Osterreicher, Juliane Halangk, et al.
Pageof 64